Physician profile
David Kenneth Scales
NPI 1164412029
$4,155.42
in general payments reported to CMS, 2019-2025
17 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,042 · 2020: $97.77 · 2021: $83.66 · 2022: $173 · 2023: $481 · 2024: $47.58 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thrombogenics, INC. | $1,607.63 | 2019 | |
| Mallinckrodt Enterprises LLC | $926.71 | 2019 | |
| Astellas Pharma US INC | $427.75 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $264.35 | 2019-2020 | |
| Genentech USA, INC. | $171.63 | 2019-2023 | Vabysmo |
| Eyepoint US, INC. | $131.68 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $130.61 | 2023-2025 | Eylea Hd, Eylea |
| Heidelberg Engineering, INC. | $122.80 | 2019 | |
| Alimera Sciences, INC. | $70.86 | 2019-2023 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.35 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $66.10 | 2024-2025 | Acthar |
| Allergan, INC. | $51.50 | 2020-2021 | |
| Gilead Sciences, INC. | $33.48 | 2019 | |
| Apellis Pharmaceuticals, INC. | $22.24 | 2023 | Syfovre |
| Ani Pharmaceuticals, INC. | $22.24 | 2023 | Purified Cortrophin Gel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $20.30 | 2020 | |
| Bausch & Lomb Americas INC. | $15.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.